Should ASX investors buy the dip in the CSL share price?

The biotech is down 9% so far in 2022.

| More on:
A young woman wearing a red and white striped t-shirt puts her hand to her chin and looks sideways as she wonders whether to buy NAB shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares are down by 9% year-to-date 
  • Brokers are constructive on the company and reckon there's plenty of growth to come
  • CSL finished the session on Thursday at $264.95 per share 

The CSL Limited (ASX: CSL) share price finished the session in the green on Thursday at $264.95, up 0.76%. For many years, this blue-chip behemoth has been a star performer of the ASX. Over the five years leading up to the COVID-19 market meltdown in March 2020, CSL stock ascended by almost 200%.

The pandemic has sent this ASX biotech share on a rollercoaster ride. In the past 12 months, CSL shares reached a 52-week high of $319.78 in November 2021. They then took a tumble to a 52-week low of $240.10 in February. In the year to date, the CSL share price is down by 9%.

Which begs the question: Should you buy the dip?

TradingView Chart

A 9% discount year-to-date

A 9% dip might not sound significant for an expensive stock like CSL but consider this. Before the pandemic, the CSL share price peaked at an all-time high of $342.75 — which might make today's price of $264-ish look a little different in terms of a potential buying opportunity.

And here's what the experts have to say.

Analysts at Citi recently retained their buy rating on CSL and valued the company at $335 per share. That's an enormous price target that signifies a 26% total shareholder return if it were to eventuate.

"Over the next six months, we expect the market to focus on the strong underlying plasma market demand, and the closure of the Vifor deal, both of which should lead to strength in the share price," the broker commented in a recent note.

Citi joins an extensive list of analysts advocating CSL, with 87% of coverage saying buy and just 12.5% saying sell. The consensus price target is $316.60, so Citi sits above the consensus with its analysis. So does Macquarie.

What does Macquarie think of the CSL share price?

The broker is bullish on CSL and reckons there will be a strong growth trajectory until FY24, given a variety of catalysts.

It recently noted that CSL's acquisition of Vifor Pharma lends the biotech giant opportunities in the iron deficiency and kidney disease segments. Not only that, but the Vifor buy enables CSL to diversify into new markets whilst adding new opportunities for research and development (R&D).

It prices CSL at $327 per share on a buy rating, aloft consensus, but not too far off the share's 52-week high of $319 in November.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »